Smart Inhalers Market size was valued to be at $34
million in 2018 and is expected to increase during the forecast period to be at
$1,406 million by 2026, registering a CAGR of 58.4% from 2019 to 2026. The
inhalers segment accounted for more than half of the total market share in
2018.
Smart inhalers are the small inhaler devices
used for delivering several inhaled medications such as anticholinergics,
glucocorticoids, and beta antagonists. According to CDC data of 2016,
approximately 26.5 million people are living with asthma in the U.S., and
nearly 1.7 million people were found out to be having asthma as the primary
diagnosis during their visit to emergency departments. Smart inhalers contain
sensors that are connected to inhaler devices, this allows maintaining the
record of inhaler, increasing the adherence and monitoring of the patient.
The major factor attributing to the increase
of smart inhalers is rise in prevalence of COPD and asthma, among which COPD is
expected to be the third leading cause of death globally by 2030. Better
treatment option, ease of use, and technological advancements coupled with increase
in adherence rate of patients to smart inhalers are other major factors that
drive this market. However, lack of reimbursement for smart inhalers and
limited availability of smart inhalers in developing regions are expected to
restrain the global smart inhalers market growth.
Currently, Adherium is the major player in
this market with majority of the approved products being provided by Adherium.
However, smart inhalers being a lucrative market, acquisitions and
collaborations are increasing between the pharmaceutical companies and smart
inhaler manufacturers.
Based on distribution channel, the market is
segmented into hospitals, retail pharmacies, and online pharmacies. Retail
pharmacies segment is the highest contributor for the distribution channel
segment. However, online pharmacies segment is the highest growing segment and
is expected to propagate at a higher growth rate throughout the forecast
period, owing to the preference over other pharmacies, as it provides hassle
free doorstep delivery of the smart inhalers directly by the manufacturing
companies.
This report provides a comprehensive
analysis of the key players operating in this market. These include Adherium,
Astrazeneca plc., Glaxo Smith Kline, Cohero Health Inc., Novartis International
AG, ResMed Inc., Opko Health Inc., Boehringer Ingelheim Group, and Vectura
Group plc.
Key Findings of the Smart
Inhalers Market Study:
- North America occupied more than
one-third share of the global smart inhalers market in 2018.
- The inhalers segment is the highest
contributor in the product segment.
- The online pharmacies in the distribution
channel segment is anticipated to grow with the highest CAGR throughout
the forecast period.
- The hospitals in the distribution channel
segment accounted for three-fourths share of the market in 2018.
- The nebulizers in the by product segment
is anticipated to grow with the highest rate throughout the forecast
period.
- Asthma in by indication type segment
accounted for the largest growth for the market.
No comments:
Post a Comment